Outcomes of Intercalary Endoprostheses as a Treatment for
Metastases in the Femoral and Humeral Diaphysis

J 2022

Outcomes of Intercalary Endoprostheses as a Treatment for Metastases in the Femoral and Humeral Diaphysis

MAHDAL, Michal, Lukáš PAZOUREK, Vasileios APOSTOLOPOULOS, Dagmar ADÁMKOVÁ KRÁKOROVÁ, Iva STANICZKOVÁ ZAMBO et. al.

Basic information

Original name

Outcomes of Intercalary Endoprostheses as a Treatment for Metastases in the Femoral and Humeral Diaphysis

Authors

MAHDAL, Michal (203 Czech Republic, belonging to the institution), Lukáš PAZOUREK (203 Czech Republic, belonging to the institution), Vasileios APOSTOLOPOULOS (203 Czech Republic, belonging to the institution), Dagmar ADÁMKOVÁ KRÁKOROVÁ (203 Czech Republic), Iva STANICZKOVÁ ZAMBO (203 Czech Republic, belonging to the institution) and Tomáš TOMÁŠ (203 Czech Republic, guarantor, belonging to the institution)

Edition

CURRENT ONCOLOGY, Basel, MDPI, 2022, 1198-0052

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.600

RIV identification code

RIV/00216224:14110/22:00127136

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.3390/curroncol29050284

UT WoS

000801930500001

Keywords in English

bone neoplasm; metastasis; diaphysis of long bones; intercalary endoprosthesis

Abstract

V originále

The purpose of this study was to evaluate the implant survival, functional score and complications of intercalary endoprostheses implanted for metastatic involvement of the femoral and humeral diaphysis. The mean follow-up was 29.8 months. In our group of 25 patients with 27 intercalary endoprostheses (18 femurs, 9 humeri), there were 7 implant-related complications (25.9%), which were more common on the humerus (4 cases, 44.4%) than on the femur (3 cases, 16.7%). Only type II failure—aseptic loosening (5 cases, 18.5%)—and type III failure—structural failure (2 cases, 7.4%)—occurred. There was a significantly higher risk of aseptic loosening of the endoprosthesis in the humerus compared with that in the femur (odds ratio 13.79, 95% confidence interval 1.22–151.05, p = 0.0297). The overall cumulative implant survival was 92% 1 year after surgery and 72% 5 years after surgery. The average MSTS score was 82%. The MSTS score was significantly lower (p = 0.008) in the humerus (75.9%) than in the femur (84.8%). The resection of bone metastases and replacement with intercalary endoprosthesis has excellent immediate functional results with an acceptable level of complications in prognostically favourable patients.

Citovat

MAHDAL, Michal, Lukáš PAZOUREK, Vasileios APOSTOLOPOULOS, Dagmar ADÁMKOVÁ KRÁKOROVÁ, Iva STANICZKOVÁ ZAMBO and Tomáš TOMÁŠ. Outcomes of Intercalary Endoprostheses as a Treatment for Metastases in the Femoral and Humeral Diaphysis. CURRENT ONCOLOGY. Basel: MDPI, 2022, vol. 29, No 5, p. 3519-3530. ISSN 1198-0052. Available from: https://dx.doi.org/10.3390/curroncol29050284.

@article{2231013,
   author = {Mahdal, Michal and Pazourek, Lukáš and Apostolopoulos, Vasileios and Adámková Krákorová, Dagmar and Staniczková Zambo, Iva and Tomáš, Tomáš},
   article_location = {Basel},
   article_number = {5},
   doi = {http://dx.doi.org/10.3390/curroncol29050284},
   keywords = {bone neoplasm; metastasis; diaphysis of long bones; intercalary endoprosthesis},
   language = {eng},
   issn = {1198-0052},
   journal = {CURRENT ONCOLOGY},
   title = {Outcomes of Intercalary Endoprostheses as a Treatment for Metastases in the Femoral and Humeral Diaphysis},
   url = {http://www.mdpi.com/1718-7729/29/5/284/htm},
   volume = {29},
   year = {2022}
}

TY  - JOUR
ID  - 2231013
AU  - Mahdal, Michal - Pazourek, Lukáš - Apostolopoulos, Vasileios - Adámková Krákorová, Dagmar - Staniczková Zambo, Iva - Tomáš, Tomáš
PY  - 2022
TI  - Outcomes of Intercalary Endoprostheses as a Treatment for Metastases in the Femoral and Humeral Diaphysis
JF  - CURRENT ONCOLOGY
VL  - 29
IS  - 5
SP  - 3519-3530
EP  - 3519-3530
PB  - MDPI
SN  - 11980052
KW  - bone neoplasm
KW  - metastasis
KW  - diaphysis of long bones
KW  - intercalary endoprosthesis
UR  - http://www.mdpi.com/1718-7729/29/5/284/htm
N2  - The purpose of this study was to evaluate the implant survival, functional score and complications of intercalary endoprostheses implanted for metastatic involvement of the femoral and humeral diaphysis. The mean follow-up was 29.8 months. In our group of 25 patients with 27 intercalary endoprostheses (18 femurs, 9 humeri), there were 7 implant-related complications (25.9%), which were more common on the humerus (4 cases, 44.4%) than on the femur (3 cases, 16.7%). Only type II failure—aseptic loosening (5 cases, 18.5%)—and type III failure—structural failure (2 cases, 7.4%)—occurred. There was a significantly higher risk of aseptic loosening of the endoprosthesis in the humerus compared with that in the femur (odds ratio 13.79, 95% confidence interval 1.22–151.05, p = 0.0297). The overall cumulative implant survival was 92% 1 year after surgery and 72% 5 years after surgery. The average MSTS score was 82%. The MSTS score was significantly lower (p = 0.008) in the humerus (75.9%) than in the femur (84.8%). The resection of bone metastases and replacement with intercalary endoprosthesis has excellent immediate functional results with an acceptable level of complications in prognostically favourable patients.
ER  -

MAHDAL, Michal, Lukáš PAZOUREK, Vasileios APOSTOLOPOULOS, Dagmar ADÁMKOVÁ KRÁKOROVÁ, Iva STANICZKOVÁ ZAMBO and Tomáš TOMÁŠ. Outcomes of Intercalary Endoprostheses as a Treatment for Metastases in the Femoral and Humeral Diaphysis. \textit{CURRENT ONCOLOGY}. Basel: MDPI, 2022, vol.~29, No~5, p.~3519-3530. ISSN~1198-0052. Available from: https://dx.doi.org/10.3390/curroncol29050284.

Detailed Information on Publication Record